All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2020-04-30T13:54:53.000Z

The FDA approves pembrolizumab for use at an additional recommended dose of 400 mg every six weeks for all previously approved adult indications

Apr 30, 2020
Share:

Bookmark this article

On April 28, 2020, the U.S. Food and Drug Administration (FDA) granted approval to pembrolizumab for use at an additional recommended dose of 400 mg every six weeks for all previously approved adult indications. This includes the treatment of adult patients with refractory classical Hodgkin lymphoma (cHL), patients with cHL who have relapsed after 3 prior lines of therapy, patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), and patients with PMBCL who have relapsed after 2 prior lines of therapy. The current dosing regimen is 200 mg of pembrolizumab intravenously every 3 weeks; this new dose option will be available to supplement the current dose.1

Pembrolizumab is a humanized monoclonal antibody that binds to programmed cell death-1 (PD-1) receptor and blocks interaction with its ligands PD-L1 and PD-L2, resulting in the activation of T lymphocytes. The new dosage approval was granted based on pharmacokinetic modeling, exposure-response, and exposure-safety data from a trial that aimed to determine whether a longer dosing interval would provide greater flexibility and convenience to patients and their healthcare providers.  Overall, 400 mg pembrolizumab administered every 6 weeks demonstrated similar pharmacokinetics and safety to the dose already approved by the FDA.2

The continued approval of the 400 mg dosage may be contingent upon verification of patient benefit in future confirmatory trials.1

Read our previous coverage of pembrolizumab’s FDA approval here and EMA approval here.

  1. FDA approves Merck’s KEYTRUDA® (pembrolizumab) for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications. https://www.mrknewsroom.com/news-release/oncology/fda-approves-mercks-keytruda-pembrolizumab-use-additional-recommended-dose-400. Published Apr 28, 2020. Accessed Apr 29, 2020.
  2. Oncology Nursing News. FDA Approves New Pembrolizumab Dosing Schedule. https://www.oncnursingnews.com/web-exclusives/fda-approves-new-pembrolizumab-dosing-schedule. Published Apr 28, 2020. Accessed Apr 29, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox